Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies | Synapse

April 4, 2024

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The number of new genome-targeted cancer drugs has increased, offering the possibility of personalized therapy, often at a very high cost.

Preguntar a la IA

Me gusta

Guardar

Compartir

Preguntar a la IA

Me gusta

Guardar

Compartir

Cite This Study

Tibau et al. (Thu,) studied this question.

synapsesocial.com/papers/68e7055ab6db64358767faaf https://doi.org/https://doi.org/10.1001/jamaoncol.2024.0194

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-20212022 · 80 citations
2Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs2011 · 69 citations
3Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples2021 · 29 citations
4Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses2014 · 213 citations
5Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions2018 · 80 citations